Use of cd36 to identify cancer subjects for treatment

A method for evaluating a subject's responsiveness to treatment with a Psap peptide, the method comprising:

• determining a level of CD36 in a sample obtained from a subject having cancer, wherein an elevated level of CD36 in the sample compared to a control level indicates that the subject is responsive to or likely to be responsive to treatment with a Psap peptide, wherein the level of CD36 in the sample is determined by performing an assay, and administering to the subject identified as responsive to or likely to be responsive to treatment with a Psap peptide an effective amount of a Psap peptide to treat the cancer;
• wherein the Psap peptide is 4 to 9 amino acids in length and comprises an amino acid sequence selected from the group consisting of CDWLPK (SEQ ID NO:
• 1), DWLPK (SEQ ID NO:
• 2), DWLP (SEQ ID NO:
• 3), and amino acid substitution variants thereof, wherein the amino acid substitution variant comprises an amino acid substitution selected from the group consisting of:
• a) Tyrosine (Y) for Tryptophan (W);
• b) an amino acid substitution for Leucine (L) selected from Valine (V), Alanine (A), or Glycine (G), or a non-canonical amino acid selected from the group consisting of methylvaline, methylleucine, or sarcosine;
• c) Arginine (R) for Lysine (K);
• d) a D-isomer of Aspartic Acid (D) for an L-isomer of Aspartic Acid (D) and/or a D-isomer of Leucine (L) for a L-isomer of Leucine (L);
• and
• e) a D-isomer of Tryptophan (W) for an L-isomer of Tryptophan (W) and/or a D-isomer of Praline (P) for an L-isomer of Proline (P).